Fully funded postdoc position in my team. CRUK and Wellcome Sanger Institute. Want to work on lung cancer + functional genomics?
Only 1 more week to apply!💥
20.01.2026 17:50
👍 1
🔁 1
💬 0
📌 0
Fully funded postdoc position in my team. CRUK and Wellcome Sanger Institute. Want to work on lung cancer + functional genomics?
Only 1 more week to apply!💥
Our paper on genetic mediators of cancer cell susceptibility to T cell killing is out today online:
www.cell.com/cell-reports...
These genes could serve as biomarkers of sensitivity to immunotherapy - they modulate IFN-g and TNF-a response and are lost in some tumours
Thread below on our preprint👇
New biomarkers for cancer immunotherapy have been identified. 🔎
Researchers found that loss of two genes, CHD1 and MAP3K7, makes tumours more likely to respond to immunotherapy.
The findings could help support more personalised cancer treatment 👇
bit.ly/4sMBTq2
new year, new job?!
Exciting postdoc position opening in my lab at the Wellcome Sanger Institute. Fully funded by CRUK
sanger.wd103.myworkdayjobs.com/en-US/Wellco...
find out more at www.coelho-lab.com
Looking to start your lab in generative biology / AI?
Come join us at the @sangerinstitute.bsky.social
Sanger is core-funded so you can generate data at scale to train the next generation of models and understanding. Design/Engineering/Chemistry/Proteins/Pathways!
pls RT
tinyurl.com/GenGenFaculty
WRN inhibitors are being tested in patients with MSI cancers. How do tumours adapt to WRN inhibition, and can therapy stay ahead of resistance?
Our latest preprint investigates how MSI tumours evolve under pressure from WRN inhibition. Highlights below.
Very neat idea to increase precision of base editors by modifying guide design, plus directed evolution!
Happen to hear your voice this morning and turned up the radio- great stuff Alex! 👏🏼
A pleasure to talk about our research today with the amazing volunteers at St John’s ambulance in aid of @cancerresearchuk.org
Wellcome Connecting Science Multiplex Assays of Variant Effects Course dates: 23-28 November 2025 Location: Wellcome Genome Campus, UK Application and bursary deadline: 18 August - apply now
Apply for Multiplex Assays of Variant Effects training by 18 August! ⏰
Join our experts to learn how to strengthen your genetic disease research or clinical work using MAVE data. 🧬
Financial assistance available💸
📎Find out more: bit.ly/3EW3lh4
#MAVE25 #VariantInterpretation
Coming up in September!
➡️Christina Kajba @ckajba.bsky.social & Michael Herger @michaelherger.bsky.social — pooled prime editing screens in haploid human cells
➡️Jon Acosta — multiplexed in vivo base editing screens
#GeneticVariants #PrimeEditing
ℹ️https://www.varianteffect.org/seminar-series/
Natural molecular glues spur next-gen small molecules for ‘undruggable’ targets www.nature.com/articles/s41...
Looking to combine ML and functional genomics to tackle cancer drug resistance? Exciting job opening at the Sanger!
sanger.wd103.myworkdayjobs.com/en-US/Wellco...
@mattcoelho.bsky.social at #VariantEffect25
🚨 Excited to share our latest preprint!
@mgarnett.bsky.social @mattcoelho.bsky.social
We introduce BEstimate, a flexible, comprehensive tool for designing and interpreting CRISPR-based editing experiments.
#CRISPR #BEstimate #BaseEditor
Magdalena Strauss at #VariantEffect25
Come and join us! We’re hiring a new Group Leader in Generative Biology at the @sangerinstitute.bsky.social
Building AI models or the data to train them?
Core funding of >$130M a year for a faculty of ~30.
www.nature.com/naturecareer...
acrobat.adobe.com/id/urn:aaid:...
pls RT!
This was a fantastic international collaboration with the @mgarnett.bsky.social, Halim and Voest teams. Thank you and congrats to all the co-authors, especially Alex, @gabrielepicco.bsky.social, Vivien and Youhani.
Finally, in patients, tumors with lower CHD1 and MAP3K7 expression responded better to cancer immunotherapy, suggesting that these genes could serve as biomarkers of response to ICB.
In mice, knocking out these genes in tumour cells led to improved responses to immune-checkpoint blockade (ICB) and increased T cell numbers and activation in tumours.
CHD1 and MAP3K7 KO additively sensitises cancer cells to IFN-g, TNF-a and T cells and are known activators of NF-kB signalling. RNA-seq revealed they regulate the transcriptional response to cytokines involving the TF CDX2, overall switching the cell response from apoptosis to cell survival.
We also identified known regulators of cytokine signalling as hits in our cytokine and T cells screens across multiple cell contexts (e.g. TBK1, SOCS1, ADAR), allowing us to compare the against CHD1 and MAP3K7 KO and unpick the signalling pathways involved in each case.
Interestingly, CHD1 and MAP3K7 are co-lost in several common cancer types, such as prostate, thyroid and melanoma (~4 %), with higher rates of loss of either gene alone.
Through integrating these data, we identify CHD1 and MAP3K7 as key determinants of resistance to T cell attack. Our individual cytokine screens and the use of JAK1/2 KO isogenic cancer cell models allowed us to deconvolute different contributions of cytokines on T cell-mediated killing.
These T cells are derived from the same patient as the tumoroids - endogenous neoantigen expression drives reactivity. Special thanks to our collaborators from the Voest lab for pioneering this sophisticated system for studying anti-tumour immunity.
We used whole-genome CRISPR/Cas9 screens in autologous primary tumoroid T cell co-cultures to investigate genes that modulate cancer cell killing by T cells.
We generated a large-scale dataset of context-specific dependencies in 4 cancer cell models, across 4 cytokines and autologous tumour-reactive T cells, collectively encompassing data from >150 whole-genome CRISPR-Cas9 screen samples.
Excited to announce our preprint today @biorxivpreprint.bsky.social
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
less than one week remaining to apply 👇